PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2012

HemaMax, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates.

Mixed / Radiation

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 22383962 ↗2012Mixed findings

HemaMax, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates.

MixedRadiationC57BL/6 mice; rhesus monkeysFemale and male mice; male rhesus monkeysn = Mouse survival n=10 per group; monkey survival five groups…SubcutaneousMice approximately 20 ng per mouse as the optimal dose, wit…24 h after total body irradiation; some groups also dosed at 48 h, 72 h or 7 da…

Model: Total body irradiation (mice 8.6-9.0 Gy; rhesus monkeys 6.7 Gy, LD50/30) with no supportive care

A single low dose of interleukin-12 given 24 h after irradiation increased survival in mice and monkeys with improved blood counts, but the highest mouse dose worsened jejunal injury.

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.